Molecular Pharmacology Program

The Alex Kentsis Lab

Share
Print
Back to Top

Research

Pictured: Alex Kentsis
Alex Kentsis, MD, PhD

We study the biology of cancers that affect children and young adults ranging from embryonal tumors in infants, leukemias and brain tumors in children, and sarcomas in young adults. Scientists in our group use inter-disciplinary experimental tools as they work to understand the fundamental causes of cancer and to develop definitive therapies for their control. Detailed information about our research is available at http://alexkentsis.net.

View Lab Overview

Kentsis Research Group

Featured News

In the Lab
Physician-scientist Alex Kentsis
Research Shows How Common Feature of Blood Cancers Can Be Targeted

In the Lab
Cancer biologist and pediatric oncologist Alex Kentsis
Analyzing Urine Can Guide the Treatment of Childhood Kidney Tumors

In the News
Gears with 2016 and 2017
Year in Review: The Science and Technology that Shaped Cancer Care in 2017

View All Featured News

Publications

Cifani P, Li Z, Luo D, Grivainis M, Intlekofer AM, Fenyö D, Kentsis A. Discovery of Protein Modifications Using Differential Tandem Mass Spectrometry Proteomics. J Proteome Research, 2021

Takao S, Forbes L, Uni M, Cheng S, Pineda JMB, Tarumoto Y, Cifani P, Minuesa G, Chen C, Kharas MG, Bradley RK, Vakoc CR, Koche RP, Kentsis A. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia. eLife, 2021

Kentsis A. Why do young people get cancer? Pediatr Blood Cancer, 2020

Kentsis A, Frank SA. Developmental Mutators and Early Onset Cancer. Front Pediatr, 2020

Ortiz MV, Ahmed S, Burns M, Henssen AG, Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan J, Letai A, He Y, Naranjo A, Chi YY, LaQuaglia M, Heaton T, Cifani P, Dome JS, Gadd S, Perlman E, Mullen E, Steen H, Kentsis A. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor. JCI Insight, 2019

View All Publications

People

Pictured: Alex Kentsis

Alex Kentsis, MD, PhD

  • Cancer biologist and pediatric oncologist Alex Kentsis leads research in the functional proteomics and molecular pharmacology of refractory childhood cancers.
  • MD, Mount Sinai School of Medicine
  • PhD, New York University
kentsisresearchgroup@gmail.com
Email Address
1-646-888-2593
Office Phone
View physician profile
Physician profile

Members

Daniel Cameron
Daniel Cameron

Research Technician

Gabriella Casalena
Gabriella Casalena

Scientific Research Manager

Shuyuan Cheng
Shuyuan Cheng

Graduate Student

Luz Jubierre Zapater, PhD
Luz Jubierre Zapater

Research Fellow

Yaniv Kazansky
Yaniv Kazansky

Graduate Student

Danmeng Luo
Danmeng Luo

Research Fellow

Victor Morell
Victor Morell

Research Technician

Helen Mueller

Research Fellow

Jack Ralls

Graduate Student

Sumiko Takao

Senior Research Scientist

Stephanie Tingue
Stephanie Tingue

Administrative Assistant

Masahiro Uni
Masahiro Uni

Research Fellow

Makiko Yamada
Makiko Yamada

Senior Research Scientist

Lab Affiliations

Achievements

  • Louise and Allston Boyer Award for Clinical Research
  • Terry Ann Krulwich Physician-Scientist Alumni Award (2020)
  • Pershing Square Sohn Prize
  • Leukemia & Lymphoma Society Scholar Award (2019)
  • Josie Robertson Investigator (2013-2018)
Read more
  • St. Baldrick’s Robert J. Arceci Innovation Award
  • Elected Member of American Society for Clinical Investigation
  • Society for Pediatric Research Young Investigator Award (2018)
  • Rita Allen Foundation Scholar Award
  • Damon Runyon Cancer Research Foundation Clinical Investigator Award (2016)
  • American Society of Hematology Scholar Award (2014)
  • Burroughs Wellcome Fund Career Award for Medical Scientists (2013)
  • Pediatric Hematology-Oncology Fellowship, Dana-Farber Cancer Institute
  • Residency in Pediatrics, Boston Children’s Hospital, Harvard Medical School
  • MD, PhD, Mount Sinai School of Medicine and New York University
  • AB, SM, University of Chicago

Lab News & Events

Upcoming event

HOPP Research Seminar

This seminar will be conducted by Zoom Webinar.

Open Positions

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Alex Kentsis discloses the following relationships and financial interests:

  • Day One Biopharmaceuticals, Inc.
    Provision of Services
  • Novartis
    Provision of Services
  • Rgenta Therapeutics Inc.
    Ownership / Equity Interests; Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: